CJC-1295 (with DAC)

Overview

CJC-1295 (With DAC) is a synthetic analogue of the endogenous Growth Hormone-Releasing Hormone ($GHRH_{1-29}). The defining characteristic of this peptide is the addition of the Drug Affinity Complex (DAC), a maleimide group that allows the peptide to covalently and reversibly bind to serum albumin after administration.

In research settings, the DAC modification is studied for its ability to significantly extend the peptide’s half-life—from minutes (as seen with native GHRH or the “No DAC” version) to several days. This makes CJC-1295 with DAC a primary tool for investigating sustained growth hormone secretion and chronic GHRH receptor activation. It is used to model long-term endocrine signaling and the effects of persistent GH/IGF-1 axis elevation without the need for frequent pulsatile administration.

Key Research Applications

CJC-1295 with DAC is utilized in complex endocrine and pharmacokinetic models:

• Extended Receptor Signaling: Investigating the effects of continuous vs. pulsatile GHRH receptor activation on somatotroph cells.
• Albumin-Binding Dynamics: Researching the pharmacokinetics of the Drug Affinity Complex and its impact on peptide stability and bioavailability.
• GH/IGF-1 Axis Modeling: Studying the long-term feedback loops between growth hormone and insulin-like growth factor 1.
• Metabolic Research: Experimental analysis of sustained GH elevation on lipid metabolism, muscle protein synthesis, and cellular repair.
• Comparative Pharmacokinetics: Serving as a long-acting reference compound in studies comparing various GHRH analogues and secretagogues.

Additional Details

• Synonyms: DAC, CJC-1295-DAC, Modified GRF 1-29 (with DAC)
• Peptide Type: GHRH Analogue (DAC-conjugated)

Handling & Reconstitution

Due to the structural sensitivity of the DAC-conjugation:

• Reconstitution: Use sterile water or an appropriate buffered aqueous solution.
• Technique: Add the diluent slowly and allow the powder to dissolve completely. Gently swirl the vial; avoid vigorous agitation or shaking, as the DAC bond is sensitive to mechanical stress.
• Stability: Post-reconstitution, store the solution refrigerated (2–8°C). Aliquot into single-use vials where possible to avoid repeated freeze-thaw cycles, which can lead to peptide degradation or aggregation.

Important Safety Information

For Research Use Only. This product is a synthetic peptide intended strictly for laboratory and in-vitro research. It is not for human or veterinary consumption, nor is it intended for diagnostic, therapeutic, or clinical applications. Researchers must follow standard laboratory safety procedures, as the extended duration of action associated with the DAC modification requires careful consideration in experimental design and animal models.

References

• Teichman S.L., Neale A., Lawrence B., Gagnon C., Castaigne J.P., Frohman L.A. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006; 91(3): 799–805. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
• Ionescu M., Frohman L.A. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 2006; 91(12): 4792–4797. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
• Alba M., Fintini D., Sagazio A., Lawrence B., Castaigne J.P., Frohman L.A., Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology – Endocrinology and Metabolism, 2006; 291(6): E1290–E1294. PMID: 16670156. https://pubmed.ncbi.nlm.nih.gov/16670156/